UK markets closed

BeiGene, Ltd. (BGNE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
308.78-3.87 (-1.24%)
At close: 4:00PM EDT

308.78 0.00 (0.00%)
After hours: 5:25PM EDT

Full screen
Trade prices are not sourced from all markets
Previous close312.65
Open314.81
Bid305.08 x 1100
Ask359.50 x 1200
Day's range307.81 - 317.79
52-week range155.16 - 388.97
Volume147,051
Avg. volume262,027
Market cap29.098B
Beta (5Y monthly)0.87
PE ratio (TTM)N/A
EPS (TTM)-13.47
Earnings date07 Aug 2018 - 13 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est361.36
  • BeiGene Highlights Progress in Hematology at EHA2021 Virtual Congress
    Business Wire

    BeiGene Highlights Progress in Hematology at EHA2021 Virtual Congress

    BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results from its broad hematology program will be presented at the 26th European Hematology Association 2021 (EHA2021) Virtual Congress being held June 9 – 17, 2021.

  • China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer
    Business Wire

    China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer

    BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its PARP inhibitor pamiparib has received conditional approval from the China National Medical Products Administration (NMPA) for the treatment of patients with germline BRCA (gBRCA) mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy. The new drug application was previously granted priority review by the Center for Drug Evaluation (CDE) in July 2020. BeiGene is preparing to launch pamiparib this month.

  • BeiGene Reports First Quarter 2021 Financial Results
    Business Wire

    BeiGene Reports First Quarter 2021 Financial Results

    BeiGene reported recent business highlights, anticipated upcoming milestones, and financial results for the first quarter of 2021.